Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMDEPKM)

• Drug Name: CP-471358 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Terminated	[1]

• Cross-matching ID:
  PubChem CID: 9869142
  TTD Drug ID: DMDEPKM

Molecule-Related Drug Atlas

Drug(s) Targeting Matrix metalloproteinase (MMP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Abametapir	DM2RX0I	Head and body lice	1G00.0	Approved	[4]
BLZ-100	DMFKA4G	Glioma	2A00.0	Phase 1/2	[5]
S-3304	DMCBQTF	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[6]
ABT-518	DMA2RM3	Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 1	[7]
D-1927	DM5D8JW	Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 1	[8]
S-3536	DMZYRI3	Osteoarthritis	FA00-FA05	Discontinued in Phase 1	[9]
BB-2983	DMYK8OG	Inflammatory bowel disease	DD72	Discontinued in Phase 1	[10]
ONO-4817	DMKRVUN	Inflammatory bowel disease	DD72	Discontinued in Phase 1	[11]
DFD-11	DMHXVN1	Head and body lice	1G00.0	Application submitted	[12]
D-9120	DMHNZ1P	Inflammatory bowel disease	DD72	Terminated	[13]

Drug(s) Affected By Collagenase 3 (MMP13)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ofloxacin	DM0VQN3	Acute gonococcal cervicitis		Approved	[14]
Clindamycin	DM15HL8	Acne vulgaris	ED80	Approved	[15]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[14]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[16]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[17]
Glucosamine	DM4ZLFD	Osteoarthritis	FA00-FA05	Approved	[18]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[19]
Doxycycline	DM7ICNU	Acne vulgaris	ED80	Approved	[15]
Acocantherin	DM7JT24	Atrial fibrillation	BC81.3	Approved	[20]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[21]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Matrix metalloproteinase (MMP)	TT1GHVO	NOUNIPROTAC	Inhibitor	[2]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Collagenase 3 (MMP13)	OTY8BZIE	MMP13_HUMAN	Gene/Protein Processing	[3]

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011348)
• [2] A phase I and pharmacologic study of the matrix metalloproteinase inhibitor CP-471,358 in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2005 Feb;55(2):136-42.
• [3] Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95.
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [5] Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
• [6] Safety, tolerability and pharmacokinetics of oral S-3304, a novel matrix metalloproteinase inhibitor, in single and multiple dose escalation studies in healthy volunteers. Int J Clin Pharmacol Ther. 2005 Jun;43(6):282-93.
• [7] Quantitative analysis of the novel anticancer drug ABT-518, a matrix metalloproteinase inhibitor, plus the screening of six metabolites in human plasma using high-performance liquid chromatography coupled with electrospray tandem mass spectrometry. J Mass Spectrom. 2004 Mar;39(3):277-88.
• [8] Correlation of antiangiogenic and antitumor efficacy of N-biphenyl sulfonyl-phenylalanine hydroxiamic acid (BPHA), an orally-active, selective matrix metalloproteinase inhibitor. Cancer Res. 1999 Mar15;59(6):1231-5.
• [9] CIINE Reflects Collagenase-Specific CII Breakdown in Cartilage Explant and Whole Body of Canine. Biomark Insights. 2013; 8: 77-83.
• [10] Matrix metalloproteinase inhibition reduces intimal hyperplasia in a porcine arteriovenous-graft model. J Vasc Surg. 2004 Feb;39(2):432-9.
• [11] ONO-4817, an orally active matrix metalloproteinase inhibitor, prevents lipopolysaccharide-induced proteoglycan release from the joint cartilage in guinea pigs. Inflamm Res. 2000 Apr;49(4):144-6.
• [12] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [13] WO patent application no. 2006,1139,93, Matrix metalloproteinase inhibitors of tgfss -induced subcapsular cataract formation.
• [14] Contrasting effects of fluoroquinolone antibiotics on the expression of the collagenases, matrix metalloproteinases (MMP)-1 and -13, in human tendon-derived cells. Rheumatology (Oxford). 2005 Dec;44(12):1514-7. doi: 10.1093/rheumatology/kei087. Epub 2005 Sep 7.
• [15] Chloramphenicol causes mitochondrial stress, decreases ATP biosynthesis, induces matrix metalloproteinase-13 expression, and solid-tumor cell invasion. Toxicol Sci. 2010 Jul;116(1):140-50. doi: 10.1093/toxsci/kfq085. Epub 2010 Mar 25.
• [16] Simvastatin inactivates beta1-integrin and extracellular signal-related kinase signaling and inhibits cell proliferation in head and neck squamous cell carcinoma cells. Cancer Sci. 2007 Jun;98(6):890-9.
• [17] Matrix metalloproteinases of epithelial origin in facial sebum of patients with acne and their regulation by isotretinoin. J Invest Dermatol. 2005 Oct;125(4):673-84. doi: 10.1111/j.0022-202X.2005.23848.x.
• [18] Glucosamine promotes chondrogenic phenotype in both chondrocytes and mesenchymal stem cells and inhibits MMP-13 expression and matrix degradation. Osteoarthritis Cartilage. 2007 Jun;15(6):646-55. doi: 10.1016/j.joca.2007.01.014. Epub 2007 Mar 6.
• [19] Identification of transcriptome signatures and biomarkers specific for potential developmental toxicants inhibiting human neural crest cell migration. Arch Toxicol. 2016 Jan;90(1):159-80.
• [20] Ouabain impairs cell migration, and invasion and alters gene expression of human osteosarcoma U-2 OS cells. Environ Toxicol. 2017 Nov;32(11):2400-2413. doi: 10.1002/tox.22453. Epub 2017 Aug 10.
• [21] Expression profiling in squamous carcinoma cells reveals pleiotropic effects of vitamin D3 analog EB1089 signaling on cell proliferation, differentiation, and immune system regulation. Mol Endocrinol. 2002 Jun;16(6):1243-56.